Frontiers in Immunology (Feb 2024)
Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells
- Zhenyu Wei,
- Jiayu Xu,
- Chengkui Zhao,
- Chengkui Zhao,
- Min Zhang,
- Nan Xu,
- Nan Xu,
- Liqing Kang,
- Liqing Kang,
- Xiaoyan Lou,
- Xiaoyan Lou,
- Lei Yu,
- Lei Yu,
- Weixing Feng
Affiliations
- Zhenyu Wei
- Intelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China
- Jiayu Xu
- Intelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China
- Chengkui Zhao
- Intelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China
- Chengkui Zhao
- Shanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China
- Min Zhang
- Intelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China
- Nan Xu
- Shanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China
- Nan Xu
- School of Chemical and Molecular Engineering, East China Normal University, Shanghai, China
- Liqing Kang
- Shanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China
- Liqing Kang
- School of Chemical and Molecular Engineering, East China Normal University, Shanghai, China
- Xiaoyan Lou
- Shanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China
- Xiaoyan Lou
- School of Chemical and Molecular Engineering, East China Normal University, Shanghai, China
- Lei Yu
- Shanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China
- Lei Yu
- School of Chemical and Molecular Engineering, East China Normal University, Shanghai, China
- Weixing Feng
- Intelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China
- DOI
- https://doi.org/10.3389/fimmu.2024.1379325
- Journal volume & issue
-
Vol. 15
Abstract
No abstracts available.Keywords
